Torno Capital’s Pacira BioSciences PCRX Stock Holding History

Torno Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,500	Closed	-$50.6K	–	344
2023 Q4	$50.6K	Buy	+1,500	New	+$43.9K	0.01%	198

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Torno Capital's PCRX Position: Q1 2024 in Review

Torno Capital sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 1,500 shares — an estimated $50.6K sold.

Torno Capital first reported a position in PCRX in Q4 2023 and held it in 1 quarter. The position peaked at $50.6K in Q4 2023. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

Torno Capital reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
Torno Capital sold 1,500 Pacira BioSciences shares in Q1 2024, an estimated $50.6K.
Torno Capital first reported a position in Pacira BioSciences in Q4 2023 and held it in 1 quarter.
Torno Capital's Pacira BioSciences position peaked at $50.6K in Q4 2023.
270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Torno Capital's 13F filing for Q1 2024, filed 15 May 2024.